GRI Bio Secures Nasdaq Compliance with $8M Offering, Approves Reverse Stock Split Amidst Delisting Concerns
Summary
GRI Bio, Inc. addressed Nasdaq's minimum stockholders' equity non-compliance by completing an $8.0 million public offering, which, while highly dilutive, brought them into compliance; shareholders also approved a reverse stock split to potentially address other listing requirements.
Key Events
-
Nasdaq Non-Compliance Addressed
The company received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement of $2.5 million.
-
Completed $8.0 Million Public Offering
GRI Bio completed a best efforts public offering on December 12, 2025, raising approximately $8.0 million in gross cash proceeds through the sale of common stock and warrants.
-
Equity Compliance Restored
As a result of the offering, the company believes its stockholders' equity now exceeds Nasdaq's $2.5 million minimum requirement, though Nasdaq will continue to monitor compliance.
-
Reverse Stock Split Approved
Shareholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split at a ratio between one-for-two and one-for-thirty, with the Board having discretion on the exact ratio and implementation.
Analysis
GRI Bio, Inc. is taking aggressive measures to maintain its Nasdaq listing, which carries significant implications for shareholders. The $8.0 million public offering, while resolving the immediate threat of delisting due to insufficient stockholders' equity, represents an extremely high level of dilution relative to the company's current market capitalization. This suggests a critical need for capital and could severely impact existing shareholder value. Furthermore, the approval of a flexible reverse stock split indicates the company is likely preparing to address the Nasdaq minimum bid price requirement, another common delisting trigger for micro-cap companies. Investors should be aware of the substantial dilution and the ongoing challenges the company faces in maintaining its public listing.
At the time of this filing, GRI was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $0.19 to $13.09. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.